MedPath

Revonto

Revonto (dantrolene sodium for injection)

Approved
Approval ID

f1650487-32bd-4017-b9c2-b38829a531af

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 7, 2021

Manufacturers
FDA

USWM, LLC

DUNS: 117542566

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

dantrolene sodium

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code78670-003
Application NumberANDA078378
Product Classification
M
Marketing Category
C73584
G
Generic Name
dantrolene sodium
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateApril 7, 2021
FDA Product Classification

INGREDIENTS (3)

dantrolene sodiumActive
Quantity: 20 mg in 60 mL
Code: 287M0347EV
Classification: ACTIB
mannitolInactive
Quantity: 3000 mg in 60 mL
Code: 3OWL53L36A
Classification: IACT
sodium hydroxideInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.